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Abstract
The purpose of this work was to study the reaction kinetics between two model sulfenamide
prodrugs of linezolid, N-(phenylthio)linezolid and N-((2-ethoxycarbonyl)ethylthio)linezolid, with
free thiol containing proteins; human serum albumin (HSA); a constitutively active mutant of the
protein tyrosine phosphatase PRL-1, PRL-1-C170-171S, a model protein; and diluted fresh human
plasma. The reaction was followed by HPLC, both for the loss of prodrug and appearance of
linezolid, and at different pH values with molar excess of the proteins relative to the prodrugs.
Pseudo first-order kinetics were observed. Consistent with earlier findings for the reaction
between similar sulfenamides and small molecule thiols, the reaction kinetics appeared to be
consistent with thiolate attack at the sulfenamide bond to release the parent drug. The proteins
reacted significantly slower on a molar basis than their small molecule counterparts. It appears that
proteins such as HSA may play a role in the in vivo conversion of sulfenamide prodrugs to their
parent drug.
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INTRODUCTION
The overall goal of this work was to determine the possible role that proteins with a free
thiol group might play in the reversion kinetics of sulfenamide model prodrugs of linezolid,
N-(phenylthio)linezolid (1) and N-((2ethoxycarbonyl)ethylthio)linezolid (2) (Figure 1).
Several previous reports established that sulfenamide prodrugs readily revert in the presence
of small molecule thiols such as glutathione and cysteine to release the parent drug and a
mixed disulfide.1–5 In vitro and in vivo studies established that the reaction was practically
instantaneous in vivo, and with glutathione and other thiols at physiological conditions in
vitro.3,5 Free thiol groups also exist on proteins. The present work attempts to measure the
reversion kinetics of 1 and 2 in the presence of commercial human serum albumin (HSA),
diluted fresh human plasma, and a free thiol-rich model protein tyrosine phosphatase,
PRL-1-C170-171S, with a thiolate rich anion at physiological pH.6 Scheme 1 describes the
proposed reaction.
Human serum albumin (HSA) has 35 cysteine residues, 34 of which are involved in
disulfide bonds and one free thiol at position-34. The free Cys-34 is readily available for
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formation of disulfide bonds with other free thiol groups, such as glutathione in vivo and is
often partially and variably oxidized during purification in commercial HSA.7–11
PRL-1 is a part of a subfamily of protein tyrosine phosphatases (PTPs) responsible for
cellular signal transduction mediating cell growth, differentiation, and tumor invasion.12–13
Our aim with the PRL-1-C170-171S mutant is to compare the reactivity of this protein to
that of commercial HSA and fresh human plasma.
EXPERIMENTAL, MATERIAL AND METHODS
Solvents and chemicals
Acetonitrile, acetone, acetic acid, formic acid, phosphoric acid, sodium phosphate (mono
and dibasic), sodium acetate, sodium formate, and sodium chloride were from Fisher
Scientific®. Cysteine, Thioglo-1® and HSA were purchased from Sigma-Aldrich®
Chemicals and used without further purification. A 25.0 mg/mL PRL-1-C170-171S protein
solution in a 50 mM phosphate buffer solution (I = 0.15) at pH 6.5 was expressed, purified
and confirmed to be active as previously described by Skinner et al.14 Purity was confirmed
to be greater than 98% by size exclusion chromatography and densitometry of SDS-PAGE
gels stained with Coomassie. A fresh human plasma sample was donated by one of us
(KNA). Water used in all experiments was freshly distilled and deionized in-house using a
Corning® Mega-pure One Liter distillation apparatus.
The synthesis of the two model, sulfenamide prodrugs, 1 and 2, was described previously,4
and reaction conditions and method of analyses were as previously described for the reaction
with small molecule thiols.5
Determination of the free thiol concentration of HSA
L-cysteine was used as a standard in a slightly modified procedure outlined by Covalent®
(Corvallis, OR) in determining the free thiol concentration present in human serum albumin
purchased from Sigma-Aldrich®. Stock solutions of L-cysteine and HSA were prepared in
distilled water to a concentration of 0.051 mM. A solution of ethanethiol, as a standard, was
also prepared in acetonitrile to a final concentration of 0.051mM. Thioglo-1® was dissolved
diluted in DMSO to give a final concentration of 0.253mM. Fifty microliters of L-cysteine
or HSA were added to 0.5mL, 1.0 mL, 2.0 mL, 3.0mL, and 4.0mL solutions of 50mM
phosphate buffer solutions at pH 7.4. Fifty microliter aliquots of the Thioglo-1® solution
were added to each sample to give a 5:1 molar ratio of Thioglo-1® to L-cysteine or HSA.
The samples were kept at 25°C and analyzed by spectrophotometer at an excitation of 360
nm and an emission of 500 nm.
Degradation of 1 in the presence of HSA
Commercial human serum albumin (HSA) solutions were prepared to a final concentration
of 40 μM in 50 mM buffer solutions (I = 0.15) at pH 5.0, 6.0, 7.0, 7.4 and 7.5. 1 was added
to give a final concentration of 4.5 μM. Aliquots of the samples (100 μL) were placed in
micro centrifuge tubes and kept in a water bath at 25°C. At appropriate time points, 100 μL
of a 1.0 mM N-methyl maleimide solution in acetonitrile was added to the 100 μL samples
in the micro centrifuge tubes to quench the reaction and also precipitate protein from the
solution. Previous controls showing excess N-methyl maleimide confirmed quantitative
quenching of the reaction between thiols and sulfenamides.5 The samples were vortexed for
15 seconds and centrifuged at 13,000 rpm for 5 minutes. The supernatant was analyzed by
HPLC.
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Degradation of 1 in the presence of PRL-1 C170-171S Mutant
PRL-1-C170-171S protein solutions were prepared as per HSA, to a final concentration of
12.4 μM. PRL-1-C170-171S was shown to only four cysteine residues; hence, at a
concentration of 12.4 μM, the concentration of free thiol present was assumed to be 49.6
μM and the reaction conditions at pH 5.5, 6.0, 6.5, 7.0, 7.4 and 7.5. Kinetics and analyses
were carried out as described for HSA.
Degradation of 1 and 2 in the presence of Human Plasma
Literature reports indicate human plasma contains 0.6 mM albumin.15 Fresh human plasma
(HP) solutions were diluted to obtain a nominal final albumin concentrations of 40 μM in 50
mM phosphate buffer solution (I = 0.15) at pH 7.4. 1 or 2 were added to give a final
concentration of 4.4 μM. Samples were quenched, handled and analyzed as per the HSA
experiments.
RESULTS AND DISCUSSION
Reversion of 1 in the presence of HSA and PRL-1-C170-171S
The addition of 1 to a 0.6 mM sample of commercial HSA at pH 7.4 and freshly harvested
fresh HSA resulted in the immediate quantitative generation of the parent linezolid
molecule. At lower HSA concentration (40 μM) the reaction was slower and hence one is
able to follow the reaction by quenching followed by HPLC analysis. Due to the molar
excess of free thiol proteins, pseudo first-order kinetics was observed for the loss of the
prodrug at all pH values studied.
A pH-rate profile for both HSA and PRL-1-C170-171S can be seen in Figure 2. Unlike what
was observed in the case with small molecule thiols and discussed in an earlier paper, the pH
dependency was more complex.5 That is, the reaction of the sulfenamide with the small
molecule thiols showed a pH dependency that was consistent with the reaction of the
thiolate anion specie with substrate sulfenamides where a semi-log plot of kobs versus pH of
solution showed a linear plot with a slope of approximately one. An apparent first order
dependency on base is expected at pH values less than the pKa of the thiol group.5 The same
plots for HSA and PRL-1-C170-171S do not exactly show this pH behavior. For HSA the
slope between experimental points changes form a slope of less than unity at lower pH
values to greater than unity between the last two pH values.
A number of possible explanations for the HSA data include; first, a change in pH of
solution can result in a change in the conformational structure of the albumin molecule, thus
changing the accessibility of the free thiol at Cys-34 to the prodrug. Second, in addition to
altering accessibility, a change in conformation may lead to a change in the residues
neighboring or surrounding the free thiol Cys-34 residue, thus significantly affecting any
ionizable groups surrounding the free Cys-34 residue and affecting factors such as the
apparent dissociation constant (Ka) of the thiol. Thus, changes in the fraction of the thiolate
form of the Cys-34 thiol will significantly change its reactivity. The prodrug may also be
capable of binding to HSA. If the prodrugs are partially or strongly bound to HSA at a
site(s) removed from Cys-34 this could also affect the reactivity of the prodrugs with HSA.
The pH of solution could alter the binding capacity of the prodrugs to HSA. Thus, while
there are many possible explanations for the pH dependency seen in figure 2, it is likely that
more than one cause is operative.
The determination of the free thiol concentration in the commercial indicated that only 30 to
45% of the thiol actually existed as a free thiol per mole of HSA, meaning that
approximately 55 to 70% of the Cys-34 was oxidized. These values are consistent with
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recent reports in which HSA from different commercial sources were tested for the free thiol
concentrations.16
The pH-rate profile for the reaction of 1 with PRL-1-C170-171S showed a linear correlation
with a positive slope (Figure 2). However, unlike small molecule thiols, which showed a
slope of unity, the slope in this case was 0.52. Based on structural studies performed using
solution NMR, minor perturbations in structure occur over the pH range used here
(unpublished data), but conformational fluctuations promote formation of an internal
disulfide bond between C49 and C104, which would decrease the number of free thiols
while one of the PRL-1-C170-171S thiols may be fully ionized over the pH-range studied.14
Degradation of 1 in the presence of HSA and PRL-1-C170-171S resulted in a half-lives
(t1/2(HSA) and t1/2(PRL-1M)) of 6.7 and 6.8 minutes at pH 7.4, respectively. A comparison of
the reactivity observed in HSA and in PRL-1 with the reactivity observed in cysteine and
glutathione indicate a significantly higher reactivity for small molecule thiols at pH 6.0 and
7.4 (Table 1).
Degradation of sulfenamide prodrugs in the presence of human plasma
In the presence of diluted human plasma (HP, nominal albumin concentrations of 40μM), 1
and 2 degraded faster than in the presence of commercial HSA (40μM). For example, 1 at
pH 7.4 had a half life of 3.7 minutes (kobs(HP) = 0.0032 sec−1) in diluted human plasma,
compared to 6.8 minutes (kobs(HSA) = 0.0017 sec−1) in commercial HSA. Similarly, 2 had
half-lives of 7.7 minutes (kobs(HP) = 0.0015 sec−1) and 27.6 (kobs(HSA) = 0.00042 sec−1)
minutes, respectively. The higher reactivity of 1 is due to the phenylthiol promoiety being a
much better leaving group, lower pKa value of 6.51 versus 9.7, compared to the 3-
mercaptopropanoate ethyl ester promoiety of 2.5 These studies were carried out at the same
nominal HSA molar concentration. However, as stated earlier, approximately 30 to 45% of
the Cys-34 in commercially available HSA actually exists in its free thiol form. Thus, the
lower reactivity is probably due to the differing states of thiol oxidation between commercial
HSA and HSA in fresh plasma. If one accounts for the lower free thiol concentration in the
HSA solution, differences in reactivity between the commercial HSA and diluted human
plasma appear negligible.
On a molar basis, small molecule thiols cleave the sulfenamide bonds more rapidly than free
thiol containing proteins (Table 1). Nevertheless, these observations suggest that albumin
and other free thiol containing proteins could play some role in the in vivo conversion of the
sulfenamide prodrugs to their parent drugs.
CONCLUSIONS
Small molecule thiols were shown to readily react with sulfenamide prodrugs to release the
parent drug and a mixed disulfide.5 Here, free thiol containing proteins (HSA and PRL-1-
C170-171S) similarly react with sulfenamide to release the parent drug, albeit at a slower
rate compared to that seen on a molar basis with small molecule thiols. Results obtained
earlier from small molecule thiols showed the formation of a mixed disulfide between the
nucleophilic thiol and the promoiety of the prodrug. One can assume that a mixed disulfide
will be formed between the thiol proteins and the sulfenyl promoieties. This may lead to
potential concerns in toxicity and immunogenicity. Further studies therefore need to be
carried out to confirm the formation of mixed disulfides between the proteins and the
sulfenyl promoieties and their possible toxic effects.
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Structures of linezolid prodrug models used in the study of sulfenamide stability in the
presence of molar excess of thiol proteins. In the reactions with thiol proteins only 1 was
used and both prodrugs were used in the reactions with diluted fresh human plasma.
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pH dependency (pH-rate profile) for the reaction of 1 in the presence of a nominal 10 fold
molar excess (assuming one free thiol per mole of HSA) of human serum albumin (HSA, □)
in 50 mM buffer solutions (I=0.15) at 25°C. Free thiol analysis of the commercial HSA used
in this study indicated that only 30 to 45% of the thiol actually existed as a free, non-
oxidized thiol per mole of HSA. Also plotted is the reaction of 1 in the presence of 2.5-fold
molar excess, or 10 fold excess in total thiols, of PRL-1-C170-171S (○) assuming four free
thiols per mole of PRL-1 C170-171S protein.
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Proposed mechanism for the reaction of 1 with cysteine thiol groups on a protein.
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Table 1
A comparison of the half lives for the reversion of 1 in the presence of nominal 40 μM of thiols (cysteine and
glutathione), and free thiol proteins at pH 6.0 and 7.4 in 50 mM phosphate buffer solutions.
Reacting Species pH 6.0 pH 7.4
Cysteine 1.4 min 4.1 sec
GSH, glutathione 2.3 min 5.4 sec
HSA 233 min 6.7 min
PRL-1-C170-171S 25.1 min 6.8 min
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